Levodopa
- Generic Name
- Levodopa
- Brand Names
- Dhivy, Duodopa, Duopa, Inbrija, Parcopa, Prolopa, Rytary, Sinemet, Stalevo
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO4
- CAS Number
- 59-92-7
- Unique Ingredient Identifier
- 46627O600J
- Background
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the b...
- Indication
Levodopa on its own is formulated as an oral inhalation powder indicated for intermittent treatment of off episodes in Parkinson's patients who are already being treated with carbidopa and levodopa. Levodopa is most commonly formulated as an oral tablet with a peripheral dopa decarboxylase inhibitor indicated for treatment of Parkinson's disease, post-enceph...
- Associated Conditions
- Paralysis agitans, Parkinson's Disease (PD), Parkinsonism, Parkinsonism post encephalitic, Restless Legs Syndrome (RLS), Advanced Motor fluctuations
- Associated Therapies
- -
Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-01-05
- Target Recruit Count
- 200
- Registration Number
- NCT00218075
- Locations
- 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States
Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 39
- Registration Number
- NCT00153972
- Locations
- 🇩🇪
Department of Nuclear Medicine at the Technical University of Dresden, Dresden, Saxony, Germany
🇩🇪Department of Neurology at the Technical University of Dresden, Dresden, Saxony, Germany
Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia
- Conditions
- First Posted Date
- 2005-05-20
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 100
- Registration Number
- NCT00111371
- Locations
- 🇩🇪
Dept. of Neurology, University Hospital of Muenster, Muenster, North-Rhine Westphalia, Germany
Improved Language Acquisition With Levodopa
- Conditions
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 20
- Registration Number
- NCT00103805
- Locations
- 🇩🇪
Dept. of Neurology, University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany
Dopaminergic Enhancement of Learning and Memory in Aphasia
- Conditions
- First Posted Date
- 2005-02-04
- Last Posted Date
- 2013-10-07
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 12
- Registration Number
- NCT00102869
- Locations
- 🇩🇪
Dept. of Neurology, University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany
Neuromodulation and Language Acquisition (Project Stage Ia)
- Conditions
- First Posted Date
- 2005-01-27
- Last Posted Date
- 2010-01-27
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 100
- Registration Number
- NCT00102284
- Locations
- 🇩🇪
Dept. of Neurology, University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
- Conditions
- First Posted Date
- 2004-11-15
- Last Posted Date
- 2010-09-29
- Lead Sponsor
- Institute for Neurodegenerative Disorders
- Target Recruit Count
- 112
- Registration Number
- NCT00096720
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Boston University Medical Center, Boston, Massachusetts, United States
🇺🇸Lahey Clinic Medical Center, Burlington, Massachusetts, United States
Timing of Levodopa Treatment in Parkinson's Disease
- Conditions
- Locations
- 🇺🇸
Columbia University Health Sciences, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.